全文获取类型
收费全文 | 127349篇 |
免费 | 9876篇 |
国内免费 | 3555篇 |
专业分类
耳鼻咽喉 | 993篇 |
儿科学 | 2333篇 |
妇产科学 | 1811篇 |
基础医学 | 7027篇 |
口腔科学 | 2884篇 |
临床医学 | 15419篇 |
内科学 | 18798篇 |
皮肤病学 | 2341篇 |
神经病学 | 6471篇 |
特种医学 | 4046篇 |
外国民族医学 | 39篇 |
外科学 | 12446篇 |
综合类 | 19149篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5864篇 |
眼科学 | 2039篇 |
药学 | 10437篇 |
85篇 | |
中国医学 | 11150篇 |
肿瘤学 | 17423篇 |
出版年
2024年 | 209篇 |
2023年 | 2236篇 |
2022年 | 3436篇 |
2021年 | 5607篇 |
2020年 | 5318篇 |
2019年 | 4751篇 |
2018年 | 4527篇 |
2017年 | 4993篇 |
2016年 | 5289篇 |
2015年 | 5052篇 |
2014年 | 9373篇 |
2013年 | 11650篇 |
2012年 | 7666篇 |
2011年 | 8082篇 |
2010年 | 6630篇 |
2009年 | 6046篇 |
2008年 | 5892篇 |
2007年 | 6321篇 |
2006年 | 5641篇 |
2005年 | 5012篇 |
2004年 | 4048篇 |
2003年 | 3668篇 |
2002年 | 3012篇 |
2001年 | 2672篇 |
2000年 | 2201篇 |
1999年 | 1732篇 |
1998年 | 1427篇 |
1997年 | 1204篇 |
1996年 | 992篇 |
1995年 | 904篇 |
1994年 | 711篇 |
1993年 | 545篇 |
1992年 | 485篇 |
1991年 | 445篇 |
1990年 | 378篇 |
1989年 | 328篇 |
1988年 | 319篇 |
1987年 | 276篇 |
1986年 | 216篇 |
1985年 | 258篇 |
1984年 | 227篇 |
1983年 | 167篇 |
1982年 | 167篇 |
1981年 | 166篇 |
1980年 | 129篇 |
1979年 | 123篇 |
1978年 | 65篇 |
1977年 | 44篇 |
1976年 | 49篇 |
1975年 | 33篇 |
排序方式: 共有10000条查询结果,搜索用时 16 毫秒
21.
22.
23.
24.
25.
《Journal of thoracic oncology》2020,15(4):618-627
IntroductionPembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC.MethodsEligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 (PD-L1)–positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review.ResultsEighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5–48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4–29.4); two patients had complete response (one with a PD-L1–positive tumor), and 14 patients had partial response (13 with PD-L1–positive tumors). The median duration of response was not reached (range, 4.1‒35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events.ConclusionsPembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. 相似文献
26.
27.
目的:观察非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)患者自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)术后应用重组人α-2b干扰素(α-2b IFN)进行早期干预治疗的临床疗效。方法:选取18例行ASCT的NHL患者为研究对象,移植前疾病评估均未达到完全缓解(complete remission,CR),试验组血象恢复后给予IFN 3 000 000 U次/隔日干预治疗,3个月后停用;对照组未行干扰素干预治疗,分析总体疗效及两组对比的生存情况。结果:随访中位时间为34(10~50)个月,患者中位生存时间为37(31~45)个月,3年总体无进展生存(progressive free survival,PFS)、总生存(overall survivial,OS)分别为54.7%、66.8%。ASCT后试验组1年内无疾病复发,2年内复发率为12.5%;对照组1年内复发率为20%,2年内复发率为30%。结论:NHL患者在ASCT后给予重组人α-2b IFN早期干预治疗,患者耐受性好,可能降低移植后早期复发率。 相似文献
28.
29.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献30.